Homology Medicines (NASDAQ:FIXX) Upgraded by Zacks Investment Research to Buy

Homology Medicines} stock has undergone multiple analysts rating changes in the recent past.  Homology Medicines Upgraded by Zacks Investment Research on 10/18/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Homology Medicines (NASDAQ:FIXX) Upgraded by Zacks Investment Research to Buy